CA2765810C - Antimicrobial endolysin fusion proteins - Google Patents

Antimicrobial endolysin fusion proteins Download PDF

Info

Publication number
CA2765810C
CA2765810C CA2765810A CA2765810A CA2765810C CA 2765810 C CA2765810 C CA 2765810C CA 2765810 A CA2765810 A CA 2765810A CA 2765810 A CA2765810 A CA 2765810A CA 2765810 C CA2765810 C CA 2765810C
Authority
CA
Canada
Prior art keywords
fusion protein
seq
amino acid
protein according
gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2765810A
Other languages
English (en)
French (fr)
Other versions
CA2765810A1 (en
Inventor
Stefan Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lysando AG
Original Assignee
Lysando AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lysando AG filed Critical Lysando AG
Publication of CA2765810A1 publication Critical patent/CA2765810A1/en
Application granted granted Critical
Publication of CA2765810C publication Critical patent/CA2765810C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA2765810A 2009-06-26 2010-06-28 Antimicrobial endolysin fusion proteins Active CA2765810C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09163955 2009-06-26
EP09163955.9 2009-06-26
PCT/EP2010/059152 WO2010149795A1 (en) 2009-06-26 2010-06-28 Antimicrobial agents

Publications (2)

Publication Number Publication Date
CA2765810A1 CA2765810A1 (en) 2010-12-29
CA2765810C true CA2765810C (en) 2018-10-16

Family

ID=42537604

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2765810A Active CA2765810C (en) 2009-06-26 2010-06-28 Antimicrobial endolysin fusion proteins

Country Status (13)

Country Link
US (2) US20120195872A1 (https=)
EP (2) EP2446028B1 (https=)
JP (2) JP6034188B2 (https=)
KR (1) KR101701890B1 (https=)
CN (1) CN102482655B (https=)
AU (1) AU2010264659B2 (https=)
BR (1) BRPI1015203B1 (https=)
CA (1) CA2765810C (https=)
EA (1) EA038542B1 (https=)
IL (1) IL217121B (https=)
MX (1) MX2011013453A (https=)
SG (1) SG177704A1 (https=)
WO (1) WO2010149795A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010264659B2 (en) 2009-06-26 2016-08-04 Lysando Aktiengesellschaft Antimicrobial agents
PL2445515T3 (pl) 2009-06-26 2016-10-31 Środki przeciwdrobnoustrojowe
KR20120059576A (ko) 2009-08-24 2012-06-08 뤼산도 홀딩 아게 신규한 엔도리신 ＯＢＰｇｐＬＹＳ
CA3048783C (en) 2010-09-17 2022-05-24 Tecnifar-Industria Tecnica Farmaceutica, S.A. Antibacterial phage, phage peptides and methods of use thereof
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
CN102766196B (zh) * 2011-05-06 2014-10-29 上海医药工业研究院 一组阳离子抗菌肽及其制备方法和应用
CN103361341B (zh) * 2012-03-26 2015-09-02 复旦大学附属华山医院 杀菌肽ll-37的基因工程的表达及其制备方法和用途
EP2679232A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria vaccination
EP2679677A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
US9388400B2 (en) 2012-06-29 2016-07-12 Lysando Ag Composition for use in mycobacteria diagnosis
WO2015020765A2 (en) * 2013-08-06 2015-02-12 Trustees Of Dartmouth College Unglycosylated lysostaphin variant protein
WO2015070911A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified kz144 endolysin sequence
WO2015070912A1 (en) 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
EP2904912A1 (en) * 2014-02-07 2015-08-12 Hyglos Invest GmbH Novel high pressure method with endolysin for processing of foods
EP3105322B1 (en) 2014-02-14 2018-12-12 Lysando AG Antimicrobial agents
WO2016029920A1 (en) * 2014-08-29 2016-03-03 Aarhus Universitet Positively charged co-polymers for use as antimicrobial agents
WO2016130024A1 (en) * 2015-02-13 2016-08-18 Supreme Biotechnologies Limited Endolysin expression platform
CA3022334A1 (en) * 2016-04-28 2017-11-02 Lysando Ag Antimicrobial agents against salmonella bacteria
EA201990856A1 (ru) * 2016-10-20 2019-10-31 Новые противомикробные агенты против бактерий enterococcus
MX2019011808A (es) * 2017-04-03 2020-01-09 Sasinapas Co Ltd Endolisinas de gram-negativas modificadas.
CN108018271B (zh) * 2018-01-31 2020-08-11 武汉核圣生物技术有限公司 单亚基rna聚合酶、其纯化方法及在rna合成中的应用
WO2019191633A2 (en) * 2018-03-29 2019-10-03 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
AU2019276253A1 (en) * 2018-05-30 2020-11-26 Lysando Ag Novel antimicrobial proteins
EP3840771A4 (en) * 2018-08-23 2023-04-19 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US12516309B2 (en) * 2019-10-31 2026-01-06 University Of Maryland, College Park Method of treating infections by bacteriolytic enzymes and manufacture thereof
WO2021175606A1 (en) * 2020-03-02 2021-09-10 Unilever Ip Holdings B.V. An effective anti-acne personal care composition
CA3171721A1 (en) 2020-03-19 2021-09-23 Fritz Eichenseher A stabilized protein of interest
WO2022166736A1 (zh) 2021-02-08 2022-08-11 武汉乐斯吉生物科技有限公司 噬菌体裂解酶、其嵌合物及应用
WO2022225267A1 (ko) * 2021-04-19 2022-10-27 엠브릭스 주식회사 보툴리늄 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물
CN119183372A (zh) * 2022-03-03 2024-12-24 麻省理工学院 特异性靶向痤疮丙酸杆菌的细胞壁结合蛋白
CN114540385B (zh) * 2022-03-21 2023-06-23 齐鲁工业大学 一种利用大肠杆菌产溶葡萄球菌酶的方法
CN114349870B (zh) * 2022-03-21 2022-06-03 天津辅元生物医药科技有限公司 一种兼具防粘连功效的重组抗菌肽及其制备方法和应用
WO2024241070A1 (en) 2023-05-22 2024-11-28 L'oreal Cosmetic composition comprising an endolysin and a polyvinyl alcohol
FR3152395A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et la 4-hydroxyacetophenone
FR3149207B1 (fr) 2023-06-02 2026-03-13 Oreal Composition cosmétique comprenant une endolysine et un composé de formule (I)
FR3149205B1 (fr) 2023-06-02 2026-04-24 Loreal Composition cosmétique comprenant une endolysine et un agent de charge organique
FR3149203B1 (fr) 2023-06-02 2026-03-13 Oreal Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane
EP4719330A1 (en) 2023-06-02 2026-04-08 L'oreal Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol
FR3149206B1 (fr) 2023-06-02 2026-03-13 Oreal Composition cosmétique aqueuse comprenant une endolysine et du tréhalose
FR3149209B1 (fr) 2023-06-02 2026-04-03 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
FR3149208B1 (fr) 2023-06-02 2026-03-20 Oreal Composition cosmétique, notamment aqueuse, comprenant une endolysine et un pullulane
FR3149204B1 (fr) 2023-06-02 2026-02-13 Oreal Composition cosmétique comprenant une endolysine et un tensioactif non ionique comprenant un résidu carbohydrate
FR3149202B1 (fr) 2023-06-02 2026-04-10 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile.
FR3152394B1 (fr) 2023-08-28 2026-04-24 Loreal Composition cosmétique comprenant une endolysine et des particules d’aérogel de silice hydrophobe
FR3152393B1 (fr) 2023-08-28 2026-04-24 Loreal Composition cosmétique comprenant une endolysine dérivée d’un phage de Staphylococcus aureus et une charge minérale
FR3152396A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un polyhydroxyalcane
WO2025093666A1 (en) 2023-11-01 2025-05-08 University Of Copenhagen Treatment of lymphoma
CN118421604B (zh) * 2024-05-27 2024-10-22 小白鲸(中山)生物医药有限公司 一种重组溶葡萄球菌酶突变体及其制备方法和应用
WO2026052743A1 (en) 2024-09-04 2026-03-12 Micreos Human Health B.V. Reduction of trans-epidermal water loss by a polypeptide with antibacterial properties
CN119799685B (zh) * 2024-12-27 2026-02-17 深圳先进技术研究院 一种靶向闪烁梭菌的抗菌蛋白及其制备方法与应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970006154B1 (ko) 1987-07-06 1997-04-24 루이지아나 스테이트 유니버시티 아그리컬춰럴 앤드 메카니칼 컬리지 용해성 펩티드에 의한 진핵 병원체와 신생물의 억제 및 섬유아세포와 임파구의 자극
GB8816693D0 (en) 1988-07-13 1988-08-17 Agricultural & Food Res Viral enzyme & gene
GB2255561B (en) 1991-04-20 1995-06-21 Agricultural & Food Res Lysins from bacteriophages
EP0656952B1 (en) 1992-08-21 2003-03-05 The University Of British Columbia Cationic peptides and method for production
ATE198119T1 (de) 1994-09-01 2001-01-15 Novo Nordisk As Eine grundlegende proteinzusammensetzung zur abtötung oder inhibierung mikrobieller zellen
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US20030113298A1 (en) 1997-10-31 2003-06-19 Vincent Fischetti Use of bacterial phage associated lysing proteins for the prophylactic and therapeutic treatment of various illnesses
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US6428784B1 (en) 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US6288212B1 (en) 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
US5993809A (en) * 1998-11-18 1999-11-30 Children's Hospital Medical Center Lysozyme fusion proteins in infections
WO2001000855A1 (en) 1999-06-23 2001-01-04 Ppl Therapeutics (Scotland) Ltd. Fusion proteins incorporating lysozyme
US7338936B2 (en) 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
ATE443767T1 (de) 2002-04-22 2009-10-15 Dow Global Technologies Inc Kostengünstige herstellung von peptiden
US7566447B2 (en) 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
BRPI0413833A (pt) 2003-09-11 2006-10-24 Novozymes As célula hospedeira microbiana recombinante, construção de ácido nucleico, método para produzir uma enzima e/ou um agente antimicrobiano, produto de fusão, aditivo e composição de ração animal, animal não humano transgênico ou produtos ou elementos deste, usos do produto de fusão, da co-expressão de um agente antimicrobiano e uma enzima, e de um peptìdeo de proteção, e, método para identificar um peptìdeo de proteção
WO2005108563A2 (en) 2004-04-19 2005-11-17 University Of Chicago Peptidoglycan-hydrolyzing protein encoded by bacteriophage n4
US7572602B1 (en) 2004-12-03 2009-08-11 The United States Of America As Represented By The Secretary Of Agriculture Nucleic acid encoding endolysin fusion protein
DE102005040347A1 (de) 2005-08-25 2007-03-01 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von Listerien
ATE470451T1 (de) 2006-03-31 2010-06-15 Univ St Andrews Antimikrobielle zusammensetzungen mit einem kationischen peptid und glycylglycin- endopeptidase
DE102006061002A1 (de) 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
CN107129524B (zh) * 2007-09-25 2023-11-21 田园温室气体研究有限公司 用于抑制微生物细胞的疫苗和疫苗组分
JP2011504366A (ja) 2007-11-26 2011-02-10 プラント バイオサイエンス リミティド エンドリシン活性を有する新規ポリペプチド及びその使用
WO2010011960A2 (en) 2008-07-24 2010-01-28 The United State Of America, As Represented By The Secretary Of Agriculture Triple acting antimicrobials that are refractory to resistance development
EP2157100A1 (en) * 2008-08-19 2010-02-24 Profos AG Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
US8389679B2 (en) 2009-02-05 2013-03-05 The Regents Of The University Of California Targeted antimicrobial moieties
DE102010014867A1 (de) * 2009-04-17 2010-11-18 Sms Siemag Ag Verfahren zum Bereitstellen mindestens einer Arbeitswalze zum Walzen eines Walzguts
US8383102B2 (en) 2009-05-21 2013-02-26 The United States Of America As Represented By The Secretary Of Agriculture Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens
AU2010264659B2 (en) 2009-06-26 2016-08-04 Lysando Aktiengesellschaft Antimicrobial agents
PL2445515T3 (pl) 2009-06-26 2016-10-31 Środki przeciwdrobnoustrojowe
KR20120059576A (ko) 2009-08-24 2012-06-08 뤼산도 홀딩 아게 신규한 엔도리신 ＯＢＰｇｐＬＹＳ
SG184836A1 (en) 2010-04-27 2012-11-29 Lysando Ag Method of reducing biofilms
US9388400B2 (en) * 2012-06-29 2016-07-12 Lysando Ag Composition for use in mycobacteria diagnosis

Also Published As

Publication number Publication date
EP2446028B1 (en) 2018-04-04
AU2010264659B2 (en) 2016-08-04
EA201270082A1 (ru) 2012-06-29
US11136570B2 (en) 2021-10-05
IL217121B (en) 2019-08-29
CN102482655A (zh) 2012-05-30
CN102482655B (zh) 2018-04-10
CA2765810A1 (en) 2010-12-29
KR101701890B1 (ko) 2017-02-02
EP2446028A1 (en) 2012-05-02
JP6034188B2 (ja) 2016-11-30
EA038542B1 (ru) 2021-09-13
JP2012530510A (ja) 2012-12-06
JP2017018092A (ja) 2017-01-26
KR20120061802A (ko) 2012-06-13
AU2010264659A1 (en) 2011-12-15
WO2010149795A1 (en) 2010-12-29
EP3363896A1 (en) 2018-08-22
US20190218538A1 (en) 2019-07-18
MX2011013453A (es) 2012-04-11
US20120195872A1 (en) 2012-08-02
BRPI1015203B1 (pt) 2021-06-01
BRPI1015203A2 (pt) 2016-08-02
IL217121A0 (en) 2012-02-29
SG177704A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
US11136570B2 (en) Antimicrobial fusion proteins comprising an endolysin and an amphipathic peptide segment
AU2018201931B2 (en) Antimicrobial Agents
AU2011347152B2 (en) Antimicrobial agents
EP2702070B1 (en) New antimicrobial agents
HK1259827A1 (en) Antimicrobial agents
HK1169311B (en) Antimicrobial agents
HK1224571A (en) Antimicrobial agents
HK1224571A1 (en) Antimicrobial agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150622

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251224

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260318

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260407